• Change from baseline in mean number of micturitions, urgency urinary incontinence (UUI) episodes, incontinence episodes, urgency episodes and nighttime micturitions at Week 4, 8, 28 and 52. [ Time Frame: Weeks 4, 8, 28 and 52 ] [ Designated as safety issue: No ]
• Change from baseline in mean voided volume per micturitions at Week 4, 8, 28 and 52. [ Time Frame: Weeks 4, 8, 28 and 52 ] [ Designated as safety issue: No ]
• Safety measurement based on Adverse events, Vital signs, Clinical laboratory test, 12-lead ECG and Residual urine volume. [ Time Frame: 52 weeks ] [ Designated as safety issue: Yes ]
• Change from baseline in score of King's Health Questionnaire (KHQ) and Overactive Bladder Questionnaire (OAB-q) at Week 28 and 52. [ Time Frame: Weeks 28 and 52 ] [ Designated as safety issue: No ]
• The number of subjects shifted in Patient Perception of Bladder Condition (PPBC) responses from baseline to Week 28 and 52 assessment and its percentage. [ Time Frame: Weeks 28 and 52 ] [ Designated as safety issue: No ]
• Change from baseline in grade of PPBC at Week 28 and 52. [ Time Frame: Weeks 28 and 52 ] [ Designated as safety issue: No ]

To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.

Inclusion Criteria:

• Adult OAB patients who present with OAB symptoms, including micturitions >= 8 per day and urinary urgency episodes >=1 per day.

Exclusion Criteria:

• Patient has known hypersensitivity to the active substance (fesoterodine fumarate) or to peanut or soya or any of the excipients.
• Patient has a known neurological disease influencing bladder function.
• Patient has a complication of lower urinary tract pathology potentially responsible for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic organ prolapse.